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Intensity Modulated Radiotherapy (IMRT) is the standard of care in the treatment of head and neck squamous cell carcinomas
(HNSCC) based on level 1 evidence. Technical advances in radiotherapy have revolutionized the treatment of HNSCC, with the
most tangible gain being a reduction in long term morbidity. However, these beneﬁts come with a serious and sobering price.
Today, there is a greater chance of missing the target/tumor due to uncertainties in target volume deﬁnition by the clinician that
is demanded by the highly conformal planning process involved with IMRT. Unless this is urgently addressed, our patients would
be better served with the historically practiced non conformal radiotherapy, than IMRT which promises lesser morbidity. Image
guidedradiotherapy(IGRT)ensuresthelevelofsetupaccuracywarrantedtodeliverahighlyconformaltreatmentplanandshould
be utilized with IMRT, where feasible. Proton therapy has a theoretical physical advantage over photon therapy due to a lack of
“exit dose”. However, clinical data supporting the routine use of this technology for HNSCC are currently sparse. The purpose of
this article is to review the literature, discuss the salient issues and make recommendations that address the gaps in knowledge.
1.Introduction
Radiotherapy with or without chemotherapy is the only
curative nonsurgical treatment for head and neck squamous
cell carcinomas (HNSCCs) and achieves high rates of local
tumor control of over 80% for stage 1-2 and 60–70% for
stage 3-4 [1]. Technical advances in radiotherapy during the
last decade and a half have revolutionized the treatment
of HNSCC. The most tangible clinical gain has been a
distinct reduction in long-term morbidity in these patients.
This, in large part, is almost a direct consequence of highly
conformal intensity modulated radiation treatment (IMRT)
planning designed to treat tumors and regions at risk
for microscopic spread while sparing uninvolved normal
structures, in particular, the salivary glands. Randomized
controlled trials [1–3] demonstrating a superior morbidity
proﬁle in patients treated by IMRT compared to his-
torical/conventional radiation treatment (HRT) techniques
have established IMRT as the current standard of care
in the treatment of HNSCC. However, there are several
caveats involving the safe utilization of IMRT including
target volume deﬁnition by the clinician which will be a
subject of discussion in this paper. On-board daily imaging,
for example, with cone beam CT is another noteworthy
advance that has made image-guided radiotherapy (IGRT)
practical and ensures the level of accuracy warranted to
deliver a highly conformal treatment plan. The beneﬁts
and limitations of IGRT are addressed. During a course
of radiotherapy, targets as well as normal structures may
undergo deformations, and adapting to these changes with
replanning is being investigated by several centers. Proton
therapy is becoming increasingly available as a number of
centers have been built in the last few years and several
more are being planned or under construction. There are
theoretical physical advantages of protons over photons,
although clinical data are sparse and the cost is signiﬁcant.
The indications for proton therapy in the treatment of
HNSCC are currently not well deﬁned, and the available data
is discussed.
2. Intensity-Modulated
Radiation Therapy (IMRT)
IMRT is a conformal 3-dimensional technique capable of
precisely targeting tumors while avoiding normal structures2 Journal of Oncology
(a) (b)
Figure 1: Comparison of a HRT plan (a) with an IMRT plan (b). Red color wash is the high-risk clinical target volume (CTV 66). Green
color wash is the low-risk target volume (CTV 54) for microscopic disease. CTV66 is covered conformally by the red 98% isodose line in the
IMRT plan. In the HRT plan conformality is lacking as the 98% isodose line covers not only CTV66 but also CTV54 as well as normal tissue
including the mandible and oral mucosa. The magenta isodose line is an undesirable 105% “hot spot” located on the mandible and in the
posterior neck in conventional plan. There are no “hot spots” in the IMRT plan.
and is the current standard of care in the treatment of
HNSCC.IMRTreferstoacontrolledmodulationofintensity
across each individual beam so that the desired high-dose
distribution matches the tumor/target in all physical dimen-
sions.Advancesincomputerizedtreatmentplanningsystems
utilizing complex inverse planning algorithms, along with
hardware improvisations including high-resolution multi-
leaf collimators, have made this technique readily available
for routine use at most centers in the developed world. The
major beneﬁt of IMRT compared to HRT is the sparing of
critical structures while conforming the desired high doses
to the tumors; an example is seen in Figure 1.
The most prevalent and a highly distressing long-term
complication after radiotherapy for HNSCC is xerostomia
[4].Inadditiontoasubjectiveperceptionofadrymouththat
is unpleasant for most, lack of saliva also makes it diﬃcult
to speak, swallow, taste, chew, and wear dentures. It may
contributetonutritionaldeﬁciencies,predisposingtopainful
mucosal ﬁssures and ulcerations, and adversely aﬀects oral
health, promoting dental caries, and the consequential
dental extractions may contribute to osteoradionecrosis.
Xerostomia is associated with signiﬁcant deterioration in
the patient’s quality of life [4]. In selected patients IMRT
can successfully spare the salivary glands mitigating these
debilitating eﬀects of xerostomia. Prospective randomized
clinical trials [1–3] have demonstrated that IMRT is sig-
niﬁcantly superior to HRT in sparing parotid glands and
the consequential recovery of salivary function, reducing
the incidence of xerostomia with marked improvements in
associated quality of life. IMRT can also spare other normal
structures such as cochlea, oral mucosa, temporomandibular
joint, and mandible [5, 6]. IMRT is expected to reduce
the frequency of osteoradionecrosis [7]a n dm a yd e c r e a s e
dysphagia by reducing the doses delivered to pharyngeal
constrictor muscles [8]. Although IMRT allows for better
conformity of the high-dose region to the tumor, it does
so at the expense of delivering low doses to a greater
volume of normal tissue. This “low dose spill” into nontarget
structures may result in unexpected and unintuitive short-
term toxicity from IMRT including alopecia and acute
mucositis in locations that were not in the beam pathways of
HRTduetothemultiplebeamanglearrangementsemployed
for IMRT as seen in Figure 2.N a u s e af r o md o s et ob r a i n
stem (area postrema) and increased acute fatigue compared
to HRT have also been reported with IMRT [1, 9]. There is
a theoretical long-term risk of increased radiation-induced
secondary malignancies due to the greater whole body
integral dose from this “low dose spill” [10].
Aswithanyprecisiontechnique,itispossibletobehighly
precise and precisely inaccurate. The greatest risk with IMRT
is to miss the tumor altogether while attempting to be very
precise in deﬁning targets and sparing normal structures.
The adage of “the most radio resistant cell being outside
the radiation portal” holds. With historical techniques, for
example, parallel opposed lateral ﬁelds matched with a
supraclavicular ﬁeld, the probability of missing the tumor
waslow,althoughthetechniquewasnotaspreciseinlimiting
dose to normal structures. Therefore, the success of such
a highly conformal planning process as IMRT is highly
sensitive to two major factors:
(1) delineation of tumor/target volume in 3 dimensions
by the clinician around which the high-dose distribution is
developed through conformal planning, and
(2) day-to-day variations in setup that could result in
the tumor “sneaking” outside of the high-dose distributionJournal of Oncology 3
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Figure 2: Typical beam arrangement applied for treating HNSCC of oropharynx with HRT on left using opposed lateral beams treating the
primary site and upper cervical nodal regions compared with multiple beam angle arrangements employed for IMRT on right. The opposed
beams do not treat through the oral cavity or the posterior scalp, and hence mucositis, is not seen in the lips and anterior oral cavity. With
IMRT mucositis may be seen in the lips as well as hair loss which is observed in the posterior scalp.
of the conformal plan, thus missing the intended treatment
dose altogether.
Several institutions have reported clinical outcome data
showing excellent local control results utilizing IMRT for
HNSCC[11].Infact,thehighlyconformaldosedistributions
achieved by IMRT may improve tumor control rates in
advanced cancers, in particular those arising from the
nasopharynx and sinonasal regions because they facilitate
the delivery of high doses to the tumor that is intimately
related to adjacent critical organs like the brainstem and
optic nerves, without exceeding the normal tissue tolerance.
However, it is unclear whether these results generated from
academic centers with a high-volume load of head and neck
cases could be generalizable to community practices that
see a lower volume and yet have embraced IMRT as the
standard of care. In an eﬀort to investigate whether the early
successes of IMRT reported by a few institutions could be
reproduced in a multi-institutional setting, the Radiation
Therapy Oncology Group (RTOG) embarked on a prospec-
t i v es t u d yo fI M R Tf o re a r l yo r o p h a r y n g e a lc a n c e r[ 12]. This
study was the ﬁrst multi-institutional trial incorporating
IMRT with participation from 14 institutions and accrued
69 patients. It included guidelines for target deﬁnition, target
dose prescription, and tissue dose constraints. The trial also
used central quality assurance (QA) processes assessing the
ability of the participating institutions to plan and execute
IMRT and the quality of the individual IMRT plans. In this
study, major target underdose deviations were associated
with a signiﬁcantly higher locoregional failure rate of 50%
compared with 6% without such deviations. As with any
technical skill, it is quite possible that a learning curve
exists in the use of IMRT and that experience gained by
treating a high case volume of patients might reduce the risk
of failure. For example, three randomized studies [13–15]
demonstrated that in a controlled clinical trial setting, larynx
preservation is possible without compromising survival in
advanced larynx or hypopharynx cancers that would have
otherwise required a total laryngectomy. As a result, this
strategy of laryngeal preservation for advanced larynx can-
cerswaswidelyembracedbytheoncologycommunity.How-
ever, recent data [16, 17] highlighted a decrease in survival
corresponding with a change in care pattern of advanced
laryngeal cancers from total laryngectomy to conservative
treatment with radiotherapy with or without chemotherapy,
especially when treated in low-volume cancer centers. This
could well be a consequence of poor case selection and/or
technical insuﬃciencies by Radiation Oncologists practicing
in the community and seeing a low-case volume. Other
studies [18–21] have identiﬁed that in head and neck and
other cancers whose treatment is predominantly driven by
technical expertise, a higher case volume is a predictor of
favorable outcome compared to a lower case volume.
The highly conformal dose distributions produced by
modulation of the beam intensity require careful delineation
of the gross tumor and high- and low-risk clinical target
volumes as well as the surrounding normal structures.
Inadequate delineation of the target volumes can diminish
tumor control or increase toxicity with IMRT. Patterns
of failure that are peculiar to parotid sparing IMRT with
unsalvageable relapses at the skull base [22] and periparotid
failures [23] have taught us the importance of recognizing
the limits of sparing normal structures and the knowledge
gaps that exist regarding microscopic tumor spread.
Contouring of target volumes can vary even among
expert radiation oncologists. Cooper et al. [24]r e p o r t e d
the discrepancies in contouring of supraglottic carcinomas
based on CT images between 8 leading experts in head and
neck cancer management including 4 radiation oncologists
and 4 neuroradiologists. The average proportion of overlap
(i.e., the degree of agreement) was approximately 50%.4 Journal of Oncology
They concluded that “the estimation of tumor shape cur-
rently is imprecise, even for experienced physicians. In
consequence, there appears to be a practical limit to the
current trend of smaller ﬁelds and tighter margins that is
typically employed with IMRT in an attempt to maximize
sparing of normal structures.” In another study comprising
of international experts involving 20 institutions in the
United States, Europe, and Asia treating HNSCC, Hong et al.
found remarkable heterogeneity in target delineation [25].
There was a ﬁvefold variation in clinical target volumes
for the ipsilateral neck (range, 35–175cm3; mean, 120cm3).
Similar variation was identiﬁed for treatment volumes in the
contralateral neck, if treated. Wide variation also existed in
the speciﬁc nodal stations included within the designated
targets. If experts disagree to the degree pointed above, one
canonlybutimaginethediscomﬁtexperiencedbyanaverage
radiation oncologist who does not see a huge volume of
HNSCC but feels obliged to treat his/her patients with the
current standard of care, that is, IMRT.
Consensus guidelines are available for delineating the
elective targets that are the presumed pathways of spread
through regional lymphatics [26, 27], but not for the high-
risk regions that immediately surround the gross tumor.
Besides, the inﬁnite subtle anatomical variations between
patients preclude replication of contours based on modal
cases that are depicted in guidelines, and clinical judgment
is required more often than not. Eisbruch et al. reported
that despite clear and well-written guidelines that were
formalized by many clinicians and physicists after consid-
erable debate, overall not a single case was judged to be
according to protocol without any variation in the RTOG
0022 study [12]. This speaks to the tremendous variation in
the interpretation of guidelines in “real life” clinical practice.
Ofcourse,imagefusionwithMRIscansandPETscanscould
further improve the accuracy of contouring, but since no
test is 100% sensitive and speciﬁc, none of these additional
tests can replace the clinical judgment that is required for
contouring. Adequate contouring skills call for a detailed
knowledge and understanding of 3-dimensional anatomy
and an ability to perform a thorough physical exam as
the extent of the gross tumor cannot be reliably gleaned
from imaging alone [28]. One is expected to learn the
art of physical examination “on the job” through clinical
rotations during residency training. However, as far as we
are aware there are no speciﬁc head and neck physical exam
training sessions in any of the radiation oncology training
programs. In addition, there are no available resources that
are instructive in “translating” physical exam ﬁndings to 3D
images that radiation oncologists rely on to contour tumor
volumes. Further discussion of this topic is beyond the scope
of this paper.
It is encouraging to note that contouring target volumes
is a skill that can be taught. Bekelman et al. [29]r e p o r t e d
on the results of a teaching intervention on a group of
11 radiation oncology residents who were primed with 2
seminars(6 ×1hrperseminar)ontheprinciplesofheadand
neck radiation oncology. They then underwent a baseline
contouring evaluation on a mock case. This was followed
by a didactic lecture and an interactive practical session.
Follow-up evaluation took place after 8–10 days on the same
baseline case. Improvements in contouring skills were noted
in all the participants for all the target volumes and 100%
adequately contoured the high-risk target volume following
the teaching intervention while only 60% of those never
completed a head and neck clinical rotation and 83% of
those who completed one could do so at baseline, although
all have been primed with 2 seminars. While the study was
limited in that it was a small sample from a highly select
group of trainees, and the gross tumors were precontoured,
it highlights important points. Despite the priming seminars
and over half the participants having gone through clinical
rotations, many failed the baseline evaluation. Second, an
eﬀectiveandtargetedteachinginterventioncouldimpartthis
essential skill.
We suggest the following for radiation oncologists treat-
ing HNSCCs with IMRT.
(1) Radiation oncologists practicing in low-volume cen-
ters are to maintain their skills periodically (e.g., annually)
by attending an intensive and targeted teaching course, for
example, ESTRO educational courses, Princess Margaret
Hospital’s IMRT course, and so forth. Currently, groups
that oﬀer such courses do not have a stringent/standardized
evaluation component to examine the learner and provide
individualized feedback for further learning and develop-
ment. It would also be advisable to establish a mentorship
relationship with a leading expert from the teaching course
to discuss complex cases and, if possible, get a virtual QA of
contours for all their IMRT cases until they achieve a level
of concordance with the expert who is mentoring them. This
is in keeping with the broad principle of continuing medical
education.
(2) For those practicing in high-volume centers, a target
volume QA program that veriﬁes individual contours is
highly desirable. For example, at the University of Wash-
ington (UW) every patient’s target volume contours are
cross-checked by an independent expert other than the
treating clinician. We also incorporate critical aspects of
physical examination during these sessions utilizing clinical
photographs and nasoendoscopy videos that are recorded
at the time of simulation. Where logistically feasible, the
independent expert also examines the patient together with
the treating clinician. Consensus target volumes are then
developed for IMRT planning.
(3)Whilepeculiarpatterns offailurehavebeenidentiﬁed
at academic centers [22, 23], the failures in the community
setting are largely unknown. It behooves every radiation
oncologist who is utilizing IMRT to carefully follow their
patients and analyze and report any failures. This is an
extremely important step for the continued development of
this novel and exciting technology.
3. Image-GuidedRadiation Therapy (IGRT)
An integral component of the treatment process that is
essential for the success of IMRT is the accuracy of patient
setup. Due to the steep dose gradients that are achievable
with IMRT, the margin for setup error is small and theJournal of Oncology 5
accuracy of daily alignment and positioning becomes even
more important as there is an increased risk for a “marginal
miss” and underdosing of the tumor as well as unintended
high doses to organs at risk.
The most basic and historical form of IGRT consisted
of two-dimensional (2D) portal images acquired in per-
pendicular/orthogonal planes to verify the position of the
isocenter, as well as the individual ﬁelds. In most cases,
these images are generated by the megavoltage (MV) beam
of the treatment machine or less frequently by a dedicated
ancillary kilovoltage (KV) unit. Bony anatomical landmarks
of the spine and skull are typically used as reference for
alignment. These images are obtained prior to treatment
at our institution on the ﬁrst 3 days of treatment and
thereafter once a week, but other schedules have also
been used. The limitations are that bony image quality is
often quite vague especially with MV imaging, and small
displacements may not be readily or reproducibly identiﬁed,
and clinical judgment is often required to interpret these
images. Historically, it is the therapists/technicians with a
limited knowledge of the cancer and the planning process
that are making these qualitative decisions regarding the
accuracy of setup. In addition, soft tissue alignment and
deformations cannot be appreciated with 2D imaging.
Recent advances in 3-dimensional or volumetric imaging
have addressed some of these issues, and cone beam CT
(CBCT) has emerged as an eﬃcient system for in-room
localization. Essentially, this consists of a compact CT
scanner that is integrated into the linear accelerator unit. A
scan can be acquired quickly, generally in 1 to 2 minutes,
just prior to treatment with the patient in the treatment
position. This scan is generally of lower resolution than a
diagnostic CT scan but provides suﬃcient bony and soft
tissue resolution for anatomic alignment. Both KV and MV
CBCT systems are available, but KV imaging provides better
image contrast and signal-noise ratio and is used at our
center. The CBCT localization scan is then superimposed
on the treatment planning CT scan utilizing a software-
based registration algorithm to verify the accuracy of setup,
and any necessary shifts are made to obtain an accurate
match. In order to circumvent setup errors IGRT that veriﬁes
the “match” between the treatment plan and ﬁnal patient
position and corrects for inaccuracies is currently being
adapted at several centers.
Treatment planning target volumes, organs at risk,
and/or any user-deﬁned regions of interest (ROI) or struc-
tures may be visualized. Bony misalignments are readily
identiﬁed, rectiﬁed, and the oﬀsets are automatically record-
ed. In addition, soft tissue deformations of tumor (e.g., due
to regression), as well as normal structures (e.g., due to
weight loss) may be identiﬁed, and it raises the possibility of
“adaptive radiotherapy” (ART) in response to these changes
(Figure 3).
Immobilization is a vital component of treatment to
decrease setup errors and facilitate safe delivery of treatment.
Standard immobilization for planning and treatment of
HNSCC is achieved with a thermoplastic mask, and it is
generally believed that this setup is stable. However, recent
studies [30, 31] have reported considerable setup variations
with a standard mask immobilization. Ahn et al. performed
repeat simulation planning scans 3 times in a series of
patients with HNSCC during their treatment course [30].
They observed signiﬁcant random positional variation in
the bony anatomy, that is skull, mandible and cervical
spine despite mask immobilization, with the eﬀects most
pronounced for the mandible and lower cervical spine.
Hong et al. reported a series of patients treated with daily
localization using an optical guidance system comprised of
an infrared radiocamera and passive ﬁducial arrays [31].
Accounting for all 6 degrees of freedom, the mean vector
oﬀset or setup error was 6.97mm (SD 3.63). They reviewed
the dosimetric impact of this on theoretical IMRT plans and
found that geographic “tumor miss” and normal tissue over-
dosing was common. Taken together, these studies call for an
improvement in the immobilization system and/or routinely
perform IGRT to verify patient positioning and ensure the
required accuracy to safely treat with an IMRT plan. Various
strategies for thermoplastic mask external immobilization
mayimpactonsetupaccuracy[32].Internalimmobilization,
where feasible should be optimized. Customized oral stents
may be used for reproducible immobilization of the tongue
in addition to their role in maximizing normal mucosal
sparing [33].
Despite mask immobilization, the ﬂexibility of the neck
and shoulders could also lead to deformations with setup
errors even with IGRT. Diﬀerential planning target volume
(PTV) margins might be necessary for diﬀerent regions of
the neck, especially with a whole neck IMRT technique.
Image registration is generally performed at the level of the
primary tumor using a bony match. However, there could
be anatomic displacements within the treatment ﬁeld at a
location that is further away from the primary site. For
example, for tonsil cancer the match is obtained at C2-3
vertebral bodies, but there could be a mismatch in the low
neck below the C6 level that is necessary to electively treat
the level 4 lymph nodes.
Ahn et al. demonstrated that there can be random
variation and semi-independent rotational and translational
movement of the skull in relation to the lower cervical
spine [30] .P o l a te ta l .e v a l u a t e dn o n r i g i ds e t u pe r r o r si n
a series of patients treated with daily CBCT with diﬀerent
regions of interest in the head and neck used for automatic
registration [34]. They found that the greatest mobility was
in the skull and mandible relative to C4–C6. Necessary
margins for compensation of this relative motion ranged
between 5 and 10mm, which exceeded typical PTV margins.
Ove et al. reviewed a series of patients undergoing IMRT
with daily image guidance using a CT-on-rails platform with
planning margins of 2–5mm [35]. Patients were generally
matched to high neck anatomy at C1-C2. They found that
a low neck point (deﬁned anatomically) relative to this
coordinatewasdisplacedbyanaverageof3.08mmanteriorly
(±0.17mm). There were signiﬁcant random setup errors in
the low neck with standard deviations of 3.9mm, 3.3mm,
and2.6mmforanterior/posterior(AP),medial/lateral(ML),
and craniocaudal (CC) displacements.
Den et al. recently reported one of the largest prospective
series to date with daily pretreatment CBCT-based IGRT6 Journal of Oncology
(a) (b)
Figure 3: (a): Patient with locally advanced nasopharyngeal cancer showing CT simulation planning CT and a corresponding daily CBCT
localization scan acquired during week 4 of treatment. Primary tumor is outlined in red. Note the interval tumor regression evident on
CBCT. (b): Superimposed planning CT and CBCT demonstrating obvious anterior-posterior misalignment before then after image-guided
correction.
in 28 patients undergoing head and neck IMRT [36]. Base
of skull lesions (nasopharynx and sinonasal) was aligned
using bony match and others (oral cavity, oropharynx, and
larynx) with grey value match. At least once a week, a post-
treatment CBCT was obtained for additional QA. CBCT
typically increased patient time on the table by no more
than 3 minutes, and this additional time on the treatment
table was tolerated well by the patients. The average shift
for pretreatment CBCT scans was 1.40, 1.66, and 1.79mm
for the ML, CC, and AP directions. Shifts of ≥3mmwere
required in 11% of setups in the ML, 14% in the CC, and
17% in the AP direction. In this study, the necessary margin
expansions from clinical target volume (CTV) to PTV in
o r d e rt oa c c o u n tf o rd a i l ys e t u pv a r i a t i o nw e r ef o u n dt ob e
3.9, 4.1, and 4.9mm in the ML, CC, and AP dimensions,
respectively, without CBCT to account for systematic and
random errors. Therefore, they recommended a minimum
of 5mm CTV to PTV margin expansion in HNSCC patients
treated without CBCT. With daily CBCT, they proposed that
marginscouldpotentiallybereducedto2-3mm.Preliminary
clinical data [37] based on 130 patients with HNSCC treated
with IMRT using a 3mm CTV to PTV expansion suggest
this is safe as they were compared with an earlier cohort
treated using a 5mm expansion. IGRT was achieved using
KVconebeamorMVfanbeamusingautomatedregistration
bone presets. There was no diﬀerence in two-year estimates
of overall survival and locoregional control, and there was
no diﬀerence in the incidence of marginal failures. Further
follow-up and additional studies will be required to conﬁrm
the safety of margin reduction with IGRT.
A reduction in margin, if performed safely, could allow
for greater sparing of normal structures. Van Asselen et al.
evaluated the impact of margin reduction on parotid preser-
vation with IMRT for oropharyngeal cancers and found that
a PTV margin reduction from 6mm to 3mm resulted in a
20% reduction in normal tissue complication probability or
about 1.3Gy mean parotid dose per 1mm [38]. It may also
open the door for dose escalation. However, extreme caution
is necessary with these highly conformal approaches given
the close association of dose and locoregional control in
HNSCC. PTV margin reduction below 5mm in the absence
of daily IGRT is probably inadequate [36, 37, 39]. Even
with IGRT, Den et al. [36] caution that tumors arising from
mobilestructures(e.g.,larynx,tongue)andpatientswholost
weight during treatment required a greater margin.
In a randomized study [1] there were greater numbers of
failures in the IMRT arm compared to HRT arm (12 versus
7) within the “high dose” ﬁeld. This study was not powered
to detect locoregional failures, and this ﬁnding was not
statistically signiﬁcant but is concerning all the same. This
study had target contouring guidelines, but the expansion
from CTV to PTV to account for day-to-day variations in
setup was only 3mm [40]. This study was conducted in the
era before the advent of modern IGRT techniques. Although
this is tantalizing data, one could reasonably speculate that
the 3mm expansion was inadequate in the absence of
rigorous daily IGRT while utilizing highly conformal IMRT
planstotreatpatients.Thefailuresthatwerecodedas“within
the high dose volume” based on the initial IMRT plan
could have actually been marginal due to the target being
marginally missed by day to day “minor” setup variations.
However, there are several other unresolved issues with
IGRT.
Varying approaches have been used with regard to the
frequency of imaging. Zeidan et al. evaluated several IGRT
protocols in patients with HNSCC with varying percentage
of fractions ranging from 0% to 50% [41]. The protocols
included no imaging, initial fraction only, initial 3 versus
5 versus 7 fractions followed by mean shift and thereafter
weekly imaging with a 3mm threshold, or imaging every
other fraction with a running mean. Image registration was
performed using a bony anatomy-based automatic fusion
algorithm. Random setup errors were not reduced for
fractions without image guidance. Protocols requiring 15–
31% of treatments to be image guided were subject to setup
errors >5mm in 26–31% of fractions and >3mm in 50–60%
of fractions. Every other day image guidance was associated
with setup errors >5mm in 11% of fractions and >3mmJournal of Oncology 7
in 29% of fractions. They concluded that systematic setup
errors were reduced with increasing frequency of image-
guidance,butnotrandomerrors.Ourinstitutionalpolicyfor
IGRT speciﬁes daily imaging to address both systematic and
random setup errors. The clinical relevance of cumulative
dose from IGRT is unclear.
The radiation dose from a single CBCT scan is almost
negligible, but the cumulative dose from frequent CBCT
imagingoveracourseof30–35treatmentsmaynotbeso.Itis
possiblethatthisadditionallowdosetonormaltissuesmight
increasetherisk ofradiation-induced secondarymalignancy,
in the same way as the theoretical risk due to the greater
whole body integral dose from the “low dose spill” from
IMRT [10]. This may be of particular concern in pediatric
patients. Currently, there is no consensus in whether this
“imaging dose” should be factored into dose calculations
during treatment planning.
The optimal approach for image acquisition for IGRT
has not been deﬁned and would depend on the speciﬁc
CBCT platform used and the needs of the individual patient.
There are a number of parameters that may impact on image
quality including the imaging ﬁeld of view (FOV), rotation
arc and acquisition time, and use of imaging ﬁlters [42]. The
methodusedforimageregistrationandevaluationcanhavea
large impact on the resulting shifts and setup accuracy. Some
of the major factors to consider are whether registration is
performed over the entire image or a speciﬁc ROI deﬁned
by a clip box, automatic versus manual matching, soft
tissue/grey-scale versus bone versus multiple ROI match-
ing, degrees of freedom available for positional correction
(i.e., translational only versus translational and rotational),
strategy for postcorrection veriﬁcation, online and/or oﬄine
corrections, and frequency of imaging. The ability and train-
ing of physicians and therapists to verify image registration
and how image guidance is integrated into a speciﬁc clinic’s
workﬂowarealsoimportantconsiderations.Familiaritywith
these issues is essential before initiating routine clinical
application.
At our institution, site-speciﬁc CBCT protocols for
image registration and setup correction for HNSCC have
been deﬁned. Based on broad general principles, we also
developedguidelinesfortheclinicalindicationsofIGRTwith
CBCT and some examples are discussed below.
IMRT Plans with Steep Dose Gradients. IMRT plans with
target volumes in close proximity to critical structures
including nasopharyngeal, nasal cavity and paranasal sinus,
orbital and periorbital tumors where PTVs are in close
proximity to brainstem, spinal cord, temporal lobes, and
optic apparatus (eyes, optic chiasm, optic nerves). Daily
CBCTensurestheaccuracyofsetupnecessarytodeliverthese
plans (Figure 4).
Bulky Exophytic Tumors. Bulky exophytic tumors often ex-
perience signiﬁcant tumor regression during the course of
treatment (Figure 3) and may beneﬁt from daily CBCT
to help guide the timing of ART and limit mucositis.
Conversely,itmaybefeasibletoidentifyresistanttumorsthat
donotregressasanticipatedandboostthemtoahigherdose.
Infrahyoid Primary Tumors. Larynx, hypopharynx, or thy-
roid cancer treatment with IMRT may beneﬁt from daily
CBCT to ensure accurate alignment with respect to the
mid/lower cervical and upper thoracic spine. Set-ups in the
lower neck below the level of the hyoid are inherently less
stable due to positional variation of the neck, and bony
anatomy is often diﬃcult to visualize in the low neck near
the clavicles on traditional port ﬁlms.
Reirradiation. It is imperative to verify accurate setup given
theelevatedriskofnormaltissuecomplications,forinstance,
tight restrictions with spinal cord tolerance dose due to prior
treatment may beneﬁt from daily CBCT.
Hypofractionated Regimens. Patients undergoing treatment
with hypofractionated regimens such as high-dose palliation
(dose per fraction >/= 3Gy and total dose >/= 45Gy) may
beneﬁt from CBCT to verify treatment accuracy given the
limitednumberofhigh-dosefractionsandtheriskofexceed-
ing critical structure tolerance with hypofractionation.
Other. There are special situations where there is concern
of unstable setup and/or diﬃcult veriﬁcation by traditional
portalimages,forinstance,apatientwithseverelyosteopenic
bones or degenerative changes that could render portal
images diﬃcult to interpret.
4. Additional Topics Pertainingto IMRT
4.1. Adaptive Radiotherapy (ART). ART is a process of
adjusting thetreatmentplanin response tochangesobserved
during radiation treatment. Deformations of targets, normal
structures as well as patient anatomy may occur during
a 6-7 week course of radiotherapy. For example, Bulky
exophytic tumors, in particular oropharyngeal tumors of
human papilloma virus origin and nasopharyngeal tumors
in the Asian population, often experience signiﬁcant tumor
regression during the course of treatment (Figure 3). It may
be feasible to replan to adjust for interval regression of the
exophytic component of the disease to limit oral mucositis.
Conversely, it may be feasible to identify resistant tumors
that do not regress as anticipated and boost them to a higher
dose. These scenarios are currently being investigated by
several groups to mitigate the problem of target deformation
duringatreatmentcourse.Apartfromphysicaldeformations
in targets, there could also be biological variations with
redistribution of tumor cells through phases of cell cycle
and reoxygenation of previously hypoxic cells converting
radio resistant cells to radiosensitive in some cases and
vice versa in others. Currently, there is no test that can
provide unambiguous information about these changes.
Other changes in patient anatomy from weight loss and
tissue edema may also occur during treatment. All these
could have an impact on the dosimetric parameters and
potentially translate to a clinically signiﬁcant impact both8 Journal of Oncology
(a) (b)
Figure 4: IMRT plan for the same patient above with a locally advanced nasopharyngeal cancer demonstrating sharp dose gradient at the
level of the skull base, clivus, and upper cervical spine in close proximity to temporal lobe brain, brainstem, and spinal cord. CBCT was used
for daily alignment to ensure setup accuracy (see Figure 3).
on tumor coverage and normal tissue toxicity. For instance,
it has been observed during the course of radiotherapy
that the parotid glands may migrate medially during a
course of radiotherapy, which may impact on the expected
versus actual doses to these structures [43]. IGRT with
CBCT provides important anatomic information during the
course of treatment, which could be the ideal platform
to facilitate ART. Currently, soft tissue resolution is quite
limited compared to bony anatomy. Although a number of
groups have reported early experience with ART for HNSCC
[44–47], the optimal strategy, frequency, and clinical impact
are not well established, and at this point in time ART is
considered explorative.
4.2. Volumetric Modulated Arc Therapy (VMAT). The tox-
icity associated with treatment of HNSCC, for example,
painful mucosal reactions, thickened secretions that are
diﬃcult to clear, dysphagia, exaggerated gagging, along with
a sensation of claustrophobic anxiety while lying under
the mask contributes to setup instability on the table
and could be associated with unrecognized intrafraction
motion. These aspects can vary from patient to patient
and should be considered in the design of PTV margins.
There is an increase in treatment time per fraction from
approximately 5–10 minutes for a conventional treatment to
20–30 minutes with IMRT. The longer a patient is on the
treatment table, the more likely he/she will move and hence
the unreliability of positioning during setup and treatment.
Emerging radiation techniques such as VMAT are capable of
generatingconformalplansthatarecomparabletoIMRTbut
use shorter treatment times that are comparable with HRT
[48].
5. Charged Particle Radiotherapy (CPR)
Unlike photon beams, charged particle beams have sharp
cutoﬀs in their range due to the intrinsic physical principles
underlying their interactions with matter. They deposit little
energy until they near the end of their range at which
point the rate of energy loss increases resulting in what is
termed a Bragg peak. Figure 5 shows the energy loss in water
for a typical megavoltage X-ray beam used in therapy, a
proton beam, and a carbon ion beam with energies set to
place the Bragg peaks at about a 20cm depth in water. For
practical clinical purposes, protons have the same biological
properties as photon beams, apart from a small scaling factor
of 1.1, which is taken to be the same for all tissues [49]. This
ignoresaverysmallregionatthedistaledgeoftheBraggpeak
where increased linear energy transfer (LET) theoretically
s h o u l dr e s u l ti na ni n c r e a s ei nr el a ti v eb i o l ogi c a le ﬀectiveness
(RBE). For heavier ions such as carbon, the high LET along
their path gives rise to higher RBEs, similar to fast neutrons,
which are both tissue and dose regimen dependent. While
the lateral beam edge is sharper for C-ions than for protons,
fragmentation eﬀects give rise to a “tail” at the distal edge of
its Bragg peak.
CPR centers utilize cyclotrons or synchrotrons to accel-
erate the particles to hundreds of MeV/amu and then direct
the beam to one of several treatment rooms. Initially, the
position of the beams was ﬁxed in the room, generally in the
horizontal direction, but more recently, rotating gantries are
used which allow the treatment of tumors located anywhere
in the body. When the particle beam emerges from the accel-
erator, it has a cross-sectionof only a fewmillimeters. Special
techniques are required to shape the beam to the target
volume. The initial approach was to use scattering devices
to spread the beam both horizontally and along the beamJournal of Oncology 9
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Figure 5: Depth dose curves for a 6MV photon beam (solid line),
a 170MeV proton beam (dashed line), and a 330MeV/amu carbon
ion beam (dotted line) as a function of depth in a water phantom.
Thebeamshavebeenarbitrarilynormalizedto100attheirmaxima.
axis [50]. Collimators and energy absorbing compensators
further shape the beam. More recently, scanning magnets
controlled by computers, coupled with beam energy control
systems,allowthescanningoftheBraggpeakthroughoutthe
targetvolumeandthedeliveryofintensitymodulatedproton
therapy (IMPT) [51–53]. This produces fewer extraneous
neutrons in the treatment room compared to the scattering
technique, something of potential importance in reducing
the risk of second malignant tumors [54].
HNSCCs are good test systems for CPR because of the
complex treatment volumes and close proximity of high-
risk regions to critical avoidance organs at risk such as
spinal cord, brain stem, and optic chiasm as well as to less
critical avoidance organs such as salivary glands, hearing
apparatus, and carotid arteries. IMRT may produce high-
dose volumes that conform well to the PTV but does so
at the cost of irradiating larger volumes of normal tissues
to low-intermediate doses [10]. In most cases, the “cost”
of irradiating this extra tissue is not well deﬁned, but as
per the ALARA (as low as reasonably achievable) principle
it would be desirable to reduce or eliminate radiation
dose to normal tissue. There are two treatment paradigms
that CPR can exploit in improving outcomes compared to
those of photon radiotherapy: (i) strive for improvements
in local/regional tumor control (which may translate into
improved survival) by increasing the dose delivered to high-
risk volumes while keeping the dose to normal tissues the
same or (ii) keep the dose to the high-risk volumes the same
with a dose reduction to normal tissues (which may translate
intoreducedtreatment-relatedmorbidity).Ofcourse,hybrid
approaches of the two may also be utilized.
While there have been multiple treatment planning
studies [55–59] showing the dose superiority of CPR to that
of photon radiotherapy, there have not been many clinical
reports on its utility for HNSCC. In general, it is diﬃcult
to lower the Dmax to normal structures (OARs) when they
were in close proximity to the high-dose GTV. It was in
the doses to OARs located some distance away from the
GTV where the CPR plans showed a major advantage over
photon radiotherapy. In addition, the dose to the skin at
the entry portal could be higher than would be expected
with IMRT. Parvathaneni et al. [55] studied 10 cases of
early stage tonsil cancers treated with unilateral technique
and compared IMRT plans with Proton therapy and found
that the maximum dose to skin with proton plans was
66Gy versus 58Gy with IMRT. The volume of skin receiving
60Gy and above with protons was 11cc versus 0.5cc with
IMRT. The proton plans were performed with passive double
scattering and most of the plans utilized 2-3 beam angles.
While these skin doses are within generally tolerable limits,
it may not always be the case for larger portals or in
complex reirradiation settings. A systematic review of the
comparative treatment planning literature identifying stud-
ies focusing on a wide variety of HNSCC types, paranasal
sinus, nasopharynx, oropharynx, larynx, and hypopharynx
[59], showed that IMPT allows for dose escalation to the
primary tumor without exceeding dose limits to OARs.
While being important contributions to the literature, we
remind the reader that simply demonstrating superior dose
distributions in treatment planning comparisons does not
substituteforclinicaltrialdatainassessingtherelativemerits
of CPR versus photon radiotherapy. In particular, CPR is
often more sensitive to daily setup variation, changes in
patient anatomy during treatment, and lack of knowledge
of whether clinically normal treatment volumes are truly at
risk for microscopic tumor spread. Moreover, the range of
i o nb e a m sc a nb ei m p a c t e db ym e t a la r t i f a c t ss u c ha sd e n t a l
prostheses and surgical reconstruction plates that are often
found in the head and neck cancer patient, something of
lesser concern in photon radiotherapy. For example, dental
ﬁllings produce an underestimation of the ion range in
the order of 3%. Tungsten prostheses are often used for
postsurgical reconstruction causing streak artifacts in the
CT images which result in errors of the order of 1% in
the calculated path length for beams passing through them.
There are a small number of articles reporting clinical
outcome data for HNSCC patients treated with CPR. Admit-
tedly these studies are often not well controlled, and many
patients were treated with a combination of photons and
protons rather than with protons alone. This, coupled with
the small patient numbers, makes it diﬃcult to draw mean-
ingful conclusions about the eﬃcacy of the CPR component.
Lin et al. describe a series of 16 patients with recurrent
tumors reirradiated with protons to doses of 59.4–70.2CGY
[60] .O v e r a l ls u r v i v a la n dl o c a l / r e g i o n a lc o n t r o la t2y e a r s
were both 50%. No CNS toxicity was noted, but sometimes
tumor coverage was compromised to ensure this. There was
an o t a b l ed i ﬀerence in overall survival at 2 years between10 Journal of Oncology
patientstreatedwith“optimal” tumorcoverage(83%)versus
“suboptimal” tumor coverage (17%). Chan et al. discuss
91 patients with advanced paranasal sinus tumors who
received combined photon and proton radiotherapy at the
Harvard Cyclotron-Massachusetts General Hospital proton
treatment center [61]. Ninety-one patients with AJCC stages
III and IV tumors were treated during the period 1988–
2002. The median prescribed dose was 73.6CGE with 49%
of the dose, on the average, being given with protons.
As a function of histology, the 3-year local control rate
was 83% for squamous cell tumors, 91% for carcinomas
having neuroendocrine features, 86% for adenoid cystic
carcinomas, and 88% for sarcomas. The overall group of
patients had a 5-year survival rate of 58% with distant failure
being the predominant pattern for relapse. A subsequent
analysis of late visual toxicity for patients with advanced sino
nasal tumors showed that the 5-year probability of having
signiﬁcant complications approached 20% when the median
tumor dose was 70CGE, and an accelerated fractionation
schema of photons and protons was utilized [62]. Because of
the heterogeneity of treatment, toxicity cannot be attributed
to either component of treatment, and one cannot judge
what would have happened if the patients would have been
treated with protons alone.
In 1991 Loma Linda University Medical Center opened
a prospective protocol using a combination of protons and
photons in an accelerated fractionation schema to treat 29
patients with locally advanced carcinomas of the oropharynx
[63]. An accelerated hyperfractionation technique similar
to the concomitant boost approach of M.D. Anderson was
utilized. A total dose of 75.9CGY was delivered in an overall
time of 28 treatment days, but only 25.5CGY of the total
dose was given with protons. No patient received concurrent
chemotherapy. Twenty-nine patients were treated over 10
years. Two-year local-regional control was 93%, and disease-
free survival was 81% with 16% of the patients having RTOG
late toxicity scores of 3. The prolonged period of time that
this study was carried out along with only about 35% of the
dose being given with protons makes it diﬃcult to ascertain
the role of proton radiotherapy.
The possible increased risk of second malignant tumor
induction with protons has been alluded to earlier in this
section, and it is certainly something of considerable interest
to those centers treating with CPR. The risk varies consid-
erably with the region of the body being treated. Yoon et
al. investigated the competing eﬀects of higher integral dose
volume for photons versus the secondary neutron bath that
is produced by proton therapy [64]. Detailed comparisons
were made between IMRT and proton radiotherapy for
selectedpatientswhoweretoreceiveprotonRTattheProton
Therapy Center in Goyang, Korea for head and neck tumors,
prostate cancer, and brain tumors. Neutron measurements
made using anthropomorphic phantoms for a proton beam
generated using the double-scattered passive technique with
a CR-39 detector were to measure the secondary neutron
dose. For IMRT treatments the secondary photon dose was
assessed by measuring ionizations as function from distance
from isocenter. Secondary cancer risk was estimated for
stomach, lung, and thyroid using a dose-response weighted
variable OED (organ equivalent dose). They found for head
and neck treatments there was a lower relative cancer risk for
all organs, even for the thyroid gland. Larger diﬀerences were
found for the other tumor sites.
Data are even sparser for carbon ions. Mizoe et al. have
reported on a phase I/II dose escalation study for patients
with advanced head and neck tumors treated with carbon
ions at HIMAC facility in Chiba, Japan [65]. A mixed group
of tumors was treated with the overall 5-year local control
rate being 75% for 34 analyzable patients. The authors
concluded that the treatment toxicity was acceptable and
comparable to what would have been expected with photon
radiotherapy. There was improved clinical outcome for
patients with nonsquamous cell tumors such as melanomas
and salivary gland tumors; the same subset of tumors
where another form of high LET radiotherapy, fast neutrons,
showed improved results compared to standard photon
radiotherapy.
Overall treatment cost is another factor to be considered
when evaluating particle radiotherapy for head and neck
cancer. Peeters et al. developed a model for evaluating
integral costs, capital and operational costs, and relative
cost per fraction for protons and C-ions compared to
photon radiotherapy [66]. They attempted to identify the
factors aﬀecting cost per fraction and then applied the
model to diﬀerent tumor sites, one of which was head and
neck cancer. The assumption was made that the particle
radiotherapy centers were fully utilized; however patients
were assumed to have “special category tumors” of greater
complexity while the photon centers were assumed to have
a mix of standard and complicated cases matching a typical
utilization spectrum. Furthermore, they assumed a 30-
year life cycle for equipment. This is appropriate for the
particle equipment but not for the linear accelerators used
in a conventional treatment center. The later would have
a typical life expectancy of 7–10 years in most business
model scenarios. One of key items in assessing a cost is the
postulated treatment time per fraction which was taken as
30 minutes for head and neck particle treatments compared
to a photon IMRT time taken of 15 minutes. The high LET
of carbon ions allows for a shorter treatment course, and so
the number of fractions was 16 for C-ions compared to 32
for protons and 33 fractions for IMRT. They found overall
costs per course for head and neck cancer to be C30,080 for
C-ions, C39,610 for protons at a proton-only facility, and
C11,520 for IMRT. As might be expected from the greater
capital cost, treating with protons at a combined C-ion—
proton facility was considerably more expensive than if the
treatment was carried out at a dedicated proton facility.
Taken together, while there is sound rationale, there is no
strong clinical data to support the routine use of CPR for the
treatment of HNSCC.
6. Conclusions
Randomized controlled trials have established IMRT as the
current standard of care in the treatment of HNSCC. While
technical advances in radiotherapy have revolutionized theJournal of Oncology 11
treatment of HNSCC with the most tangible gain being a
reduction in long-term morbidity, this success has not come
without a price. Today, there is a greater chance of missing
the target due to uncertainties in target volume deﬁnition
by the clinician. Unless this is urgently addressed, we could
be doing our patients a disservice as they would have been
better oﬀ with a cure from HRT rather than IMRT that
may be less morbid but does not cure them. We suggested
potential solutions to circumvent this issue. IGRT ensures
the level of accuracy warranted to deliver a highly conformal
treatment plan and should be utilized with IMRT, where
feasible. Guidelines for utilization of IGRT with IMRT have
been provided. Proton therapy has a theoretical physical
advantage over photon therapy. Although clinical data are
currently sparse, from a historical perspective all techniques
wheninitiallyintroducedhavesuﬀeredthisdisadvantageand
are experimental/explorative to start with. Therefore, it is
mandatory that every patient treated with this modality gets
enrolled on a clinical study and data collated meticulously so
w ec a nd o c u m e n ta n dl e a r nf r o mo u re x p e r i e n c ea n dg r o w
towards the future.
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